Focused on Hodgkin's Lymphoma, this issue delves into significant advancements in the field, including the first HRS-cell line L428 and the detection of the CD-30 antigen. It explores the role of "normal" CD30-B-lymphocytes, various chemotherapy and radiotherapy combinations, and early intensification strategies like escBEACOPP. Additionally, it discusses the potential of customized and targeted therapies, providing a comprehensive overview of current research and treatment approaches for this type of cancer.
